Prescription Drug Fair Competition Act of 2002
Latest action · Jul 29, 2002 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJul 26, 2002
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Requires applicants (pharmaceutical companies) to register their patents with the Food and Drug Administration (FDA) within 30 days of approval (or issuance for subsequently issued patents).
Makes failure to timely register a bar to civil actions for patent infringement.
Requires applications for new drugs (NDA) or abbreviated new drug applications (ANDA) which rely upon investigations not conducted by or for the applicant and which concern a patent that claims both the drug and a method of use or more than one method of use to include a certification on a claim-by-claim basis that the patent is invalid or will not be infringed (known as a Paragraph IV filing/certification) by the new drug's (generic) manufacture and a statement regarding the method(s) of use claim.
Prohibits (for subsequently issued patents) an extension of the 30 month stay of FDA approval for any new drug where an ANDA or NDA contains a Paragraph IV filing/certification and the patent holder indicates an intention to bring a patent infringement suit against the new (generic) drug's manufacturer.
Makes failure to timely file a civil action for infringement a bar to later action.
Requires the first generic applicant with a Paragraph IV filing to forfeit the 180 day marketing exclusivity period to a subsequent generic applicant if the first generic applicant engages in certain behaviors which delay or prevent the marketing of the generic drug.
Revises notice requirements for Paragraph IV filings to include and protect certain proposed formulation, composition, or method of use information.
Excludes an applicants's ability to pay damages from a court's consideration of whether or not to provide injunctive relief before the expiration of the 30 month stay of approval period.
Cosponsors 20
Members who signed on, in the order they did. Signatures ran from Jul 26, 2002 to Oct 1, 2002; 1 is an original cosponsor, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-CA | Henry A. Waxman | Original | Jul 26, 2002 |
| D-WA | Jim McDermott | Sep 10, 2002 | |
| D-NY | Nita M. Lowey | Sep 10, 2002 | |
| D-MI | Lynn N. Rivers | Sep 11, 2002 | |
| D-MA | John W. Olver | Sep 17, 2002 | |
| D-AR | Mike Ross | Sep 17, 2002 | |
| D-FL | Robert Wexler | Sep 17, 2002 | |
| D-CA | Adam B. Schiff | Sep 24, 2002 | |
| D-MA | Barney Frank | Sep 24, 2002 | |
| D-MN | Betty McCollum | Sep 24, 2002 | |
| D-WA | Brian Baird | Sep 24, 2002 | |
| D-NY | Carolyn B. Maloney | Sep 24, 2002 | |
| D-MI | Dale E. Kildee | Sep 24, 2002 | |
| D-MI | James A. Barcia | Sep 24, 2002 | |
| D-FL | Karen L. Thurman | Sep 24, 2002 | |
| D-WI | Thomas M. Barrett | Sep 24, 2002 | |
| D-CA | Bob Filner | Sep 26, 2002 | |
| D-NJ | Donald M. Payne | Sep 26, 2002 | |
| D-MO | Karen McCarthy | Sep 26, 2002 | |
| D-HI | Neil Abercrombie | Oct 1, 2002 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Jul 26, 2002 |
| Health Subcommittee | Referred Jul 29, 2002 |
Actions 3
Everything that happened, newest first.
- Jul 29, 2002Referred to the Subcommittee on Health.
- Jul 26, 2002Introduced in House
- Jul 26, 2002Referred to the House Committee on Energy and Commerce.
In the Congressional Record 1
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
| Where | In the Record | Members | Date |
|---|---|---|---|
| House | Debate and remarks H6261, H6268, H6297 | Frank Pallone, Jr. D-NJ, Sherrod Brown D-OH | Sep 17, 2002 |
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Printed hearings 2
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| Serial No. 107-140 | EXAMINING ISSUES RELATED TO COMPETITION IN THE PHARMACEUTICAL MARKETPLACE: A REVIEW OF THE FTC REPORT, GENERIC DRUG ENTRY PRIOR TO PATENT EXPIRATION146 pages | Energy and Commerce Committee | Oct 9, 2002 |
| Serial No. 107-136 | THE STEEL INDUSTRY LEGACY RELIEF ACT OF 200259 pages | Energy and Commerce Committee | Sep 10, 2002 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Food, Drug, and Cosmetic Act to provide greater access to affordable pharmaceuticals.
- Short Titles as Introduced
- Prescription Drug Fair Competition Act of 2002
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Access to health care
- Administrative procedure
- Civil actions and liability
- Commerce
- Competition
- Confidential communications
- Congress
- Congressional reporting requirements
- Damages
- Department of Health and Human Services
- Drug approvals
- Drug industry
- Drugs
- Generic drugs
- Government Operations and Politics
- Government paperwork
- Government publicity
- Health
- Injunctions
- Intellectual property
- Labeling
- Law
- Limitation of actions
- Marketing
- Patent infringement
- Patents
- Prescription pricing
- Restrictive trade practices
- Trade secrets
Text 1
Each version as it was printed, newest first.
- Jul 26, 2002Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.